113 related articles for article (PubMed ID: 6806514)
1. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
[No Abstract] [Full Text] [Related]
2. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
Morishima T; Fukada E; Nagashima N
Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
[No Abstract] [Full Text] [Related]
4. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
6. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
Ichihasi M; Mojamdar M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
[No Abstract] [Full Text] [Related]
7. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
Kanematsu S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
[TBL] [Abstract][Full Text] [Related]
8. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
Mojamdar M; Ichihashi M; Mishima Y
J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
[No Abstract] [Full Text] [Related]
9. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection.
Ito S; Kato T; Maruta K; Fujita K; Kurahashi T
J Chromatogr; 1984 Nov; 311(1):154-9. PubMed ID: 6440898
[No Abstract] [Full Text] [Related]
10. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
[TBL] [Abstract][Full Text] [Related]
11. Glutathionedopa in malignant melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(3):221-2. PubMed ID: 71825
[TBL] [Abstract][Full Text] [Related]
12. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
13. On the occurrence of cysteinyldopa and dopa in melanocytes and benign nevi cells.
Falck B; Jacobsson S; Lindvall O; Nietsche UB
Scand J Plast Reconstr Surg; 1976; 10(3):185-8. PubMed ID: 1053447
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
15. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
Aubert C; Rosengren E; Rorsman H; Rouge F; Foa C; Lipcey C
Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
[No Abstract] [Full Text] [Related]
16. 5-S-cysteinyldopa, dopa, and dopamine in the kidney and some other tissues.
Agrup G; Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1980; 60(1):63-4. PubMed ID: 6153836
[TBL] [Abstract][Full Text] [Related]
17. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
18. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Paul E; Graef V; Ruppel R; Hellwich M
Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
[TBL] [Abstract][Full Text] [Related]
19. [A newly established melanoma cell line (GAK) with 5-S-cysteinyldopa phenotype].
Nozawa S; Ohta H; Tsukazaki K; Udagawa Y; Kurihara S; Kano S
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):883-92. PubMed ID: 6431036
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of eumelanin and pheomelanin in human malignant-melanoma tissues.
Morishima T; Fukuda E
Arch Dermatol Res; 1985; 277(3):248-50. PubMed ID: 4015188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
